{"symbol":"ABT","fiscalQuarter":"Q4-2025","reportDate":"2026-01-22","reportTime":"BMO","status":"reported","company":{"name":"Abbott Laboratories","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABT/earnings/Q4-2025","postBrief":{"headline":"Abbott Labs Beats on EPS, Stock Down 10.04%","keyNumbers":[{"metric":"EPS","actual":"$1.50","expected":"N/A","surprise":"+0.20%"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged ongoing challenges in the market.","They emphasized a focus on cost management and operational efficiency."],"summary":"Overall, management expressed concern about current market conditions but highlighted efforts to maintain financial stability. They did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Abbott Labs reported better-than-expected earnings per share, but the stock dropped significantly by over 10%. Investors may be reacting to the lack of revenue details and the absence of guidance, indicating uncertainty about future performance. The defensive tone from management suggests they are cautious about upcoming challenges in the market.","metaDescription":"Abbott Labs (ABT) Q4 2025 earnings: EPS beat by 0.20%. Stock down 10.04%. Full breakdown."}}